Stockholm, February 22, 2017 — Nasdaq (Nasdaq: NDAQ) announced that Oncopeptides AB (short name: ONCO), a mid cap company within the health care sector, has started trading of its shares on the main market of Nasdaq Stockholm. Oncopeptides is the 5th company to list at Nasdaq’s Nordic markets* in 2017.
Founded in 2000, Oncopeptides is a research-based pharmaceutical company based in Stockholm, Sweden. The company’s product candidate, Ygalo, is based on the active compound melflufen and is intended for the treatment of patients with multiple myeloma – a blood cancer disease that currently has no cure. Oncopeptides is currently in late stage of its clinical development programs. For more information, please visit www.oncopeptides.se.
”We are pleased and very proud of the confidence shown in Oncopeptides by current and new institutional and private investors,” said Jakob Lindberg, CEO of Oncopeptides. “The IPO has received strong interest both in Sweden and internationally, which is a sign that investors are confident in our strategy and in our capabilities. The IPO enables us to realize our strategy to continue the development of the product candidate Ygalo for an improved treatment of late-stage relapsed and refractory multiple myeloma. Members of the management team and the board of directors look forward to continue the journey as a listed company on Nasdaq Stockholm.”
“We are pleased to welcome Oncopeptides as our second main market listing in 2017,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We continue to see a strong inflow of health care companies leveraging the public market as a platform for future expansion, and Oncopeptides is a perfect example of that.”
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables clients to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 85 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,800 listed companies with a market value of $10.1 trillion and nearly 18,000 corporate clients. To learn more, visit: business.nasdaq.com.
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
|Media Relations Contact|
|+46 73 449 78 07|